Trial Information

Association of FC-Gamma Receptor Genotypes With Response and Clinical Benefit With Addition of Rituximab to CHOP Chemotherapy in Patients With Follicular Lymphoma (FL)

OBJECTIVES:

- To test for association of polymorphisms in Fc-gamma (Fcγ) receptors IIa (H/R131) and
IIIa (V/F158) with progression-free survival and clinical response in patients with
follicular non-Hodgkin lymphoma treated with rituximab and CHOP chemotherapy comprising
cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone.

- To assess novel polymorphisms in Fcγ receptors for predictive and prognostic
significance in patients treated with this regimen.

OUTLINE: Genomic DNA extracted from paired samples of serum and formalin-fixed
paraffin-embedded tissue is analyzed for R131H polymorphism in Fcγ receptor IIa and V158F
polymorphism in Fcγ receptor IIIa by TaqMan-based assay. The DNA is also analyzed for
genotypes corresponding with several other polymorphisms in Fcγ receptors, as determined by
the HapMap project. The resulting Fcγ receptor genotypes are then compared with clinical
data from the Southwest Oncology Group database to identify associations between particular
genotypes and progression-free survival, overall response, and complete response. A
multivariate analysis incorporating clinical prognostic variables (e.g., age, stage, serum
LDH level, extranodal disease, and performance status) is also performed to determine
whether Fcγ receptor polymorphisms are independent predictive or prognostic markers for
clinical outcome.